Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.56 |
| ▸ | MAPK13 | O15264 | 13/20 | 0.56 |
| ▸ | MAPK12 | P53778 | 13/20 | 0.56 |
| ▸ | MAPK11 | Q15759 | 13/20 | 0.56 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.40 |
| ▸ | OXTR | P30559 | 1/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2196661 | 0.92 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11AVPR2 | |
| SCHEMBL2198749 | 0.90 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11AVPR2 | |
| SCHEMBL1907229 | 0.86 | MAPK14 (0.76) | MAPK14MAPK13MAPK12MAPK11AVPR2 | |
| SCHEMBL2196285 | 0.86 | MAPK14 (0.49) | MAPK14MAPK13MAPK12MAPK11AVPR2 | |
| SCHEMBL2198871 | 0.85 | MAPK14 (0.48) | MAPK14MAPK13MAPK12MAPK11AVPR2 | |
| SCHEMBL2201626 | 0.84 | MAPK13 (0.62) | MAPK14MAPK13MAPK12MAPK11AVPR2 | |
| SCHEMBL2200863 | 0.84 | MAPK13 (0.53) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2198601 | 0.83 | MAPK13 (0.63) | MAPK14MAPK13MAPK12MAPK11AVPR2 | |
| SCHEMBL27655413 | 0.81 | MAPK13 (0.47) | MAPK14MAPK13MAPK12MAPK11AVPR2 | |
| SCHEMBL1907450 | 0.78 | MAPK14 (0.81) | MAPK14MAPK13MAPK12MAPK11AVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977387-B2 | Aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2011-07-12 | — | — | US | disclosed |
| CN-1826310-B | Novel aminobenzophenone compounds | LEO PHARMA AS | 2010-07-21 | — | — | CN | disclosed |
| CN-1826310-A | Novel aminobenzophenone compounds | LEO PHARMA AS (DK) | 2006-08-30 | — | — | CN | disclosed |
| US-20060166990-A1 | Novel aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166990-A1 | Novel aminobenzophenone compounds | NFKBIA, UACA, ALDH7A1 | MAPK14 697/4885MAPK13 1063/4885MAPK12 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.